Lawrence Fong, MD of University of California, San Francisco discusses upcoming combination therapies for melanoma treatment that will be FDA approved and used in clinical practice at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.
Anti-PD1 Antibodies + IDO Inhibitor and Other Treatments in Melanoma May Be in Clinical Practice within One Year
